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ABSTRACT
Adeno-associated viruses (AAV) are thought to spread through the central nervous system (CNS) by exploiting cerebrospinal
fluid (CSF) flux and hijacking axonal transport pathways. The role of host receptors that mediate these processes is not well un-
derstood. In the current study, we utilized AAV serotype 4 (AAV4) as a model to evaluate whether ubiquitously expressed 2,3-
linked sialic acid and the developmentally regulated marker 2,8-linked polysialic acid (PSA) regulate viral transport and tropism
in the neonatal brain. Modulation of the levels of SA and PSA in cell culture studies using specific neuraminidases revealed possi-
bly opposing roles of the two glycans in AAV4 transduction. Interestingly, upon intracranial injection into lateral ventricles of
the neonatal mouse brain, a low-affinity AAV4 mutant (AAV4.18) displayed a striking shift in cellular tropism from 2,3-linked
SA ependymal lining to 2,8-linked PSA migrating progenitors in the rostral migratory stream and olfactory bulb. In addition,
this gain-of-function phenotype correlated with robust CNS spread of AAV4.18 through paravascular transport pathways. Con-
sistent with these observations, altering glycan dynamics within the brain by coadministering SA- and PSA-specific neuramini-
dases resulted in striking changes to the cellular tropisms and transduction efficiencies of both parental and mutant vectors. We
postulate that glycan signatures associated with host development can be exploited to redirect novel AAV vectors to specific cell
types in the brain.
IMPORTANCE
Viruses invade the CNS through various mechanisms. In the current study, we utilized AAV as a model to study the dynamics of
virus-carbohydrate interactions in the developing brain and their impact on viral tropism. Our findings suggest that carbohy-
drate content can be exploited to regulate viral transport and tropism in the brain.
Viruses enter the central nervous system (CNS) by exploiting avariety of transport pathways that hinge on preliminary infec-
tion of peripheral nerve endings or through the blood by infecting
circulating leukocytes or brain endothelial cells. Subsequent
spread within the brain is achieved by axonal transport and trans-
synaptic spread (1). A key step in viral entry into the CNS and
subsequent directional transport is the recognition of specific cell
surface membrane glycoproteins as receptors. For instance, polio-
viruses utilize CD155 as a receptor (2), while alpha herpesviruses
exploit nectin-1 for CNS entry (3); both of these proteins are
members of the immunoglobulin superfamily. Several mem-
brane-associated components have also been implicated in rabies
virus CNS entry (4). Prior to engagement of such host membrane
proteins, viruses often bind to cell surface glycans for attachment.
One of the most versatile host glycans that have been exploited as
viral attachment factors are the family of sialic acids (SA) (5–7).
For instance, SA receptors have been implicated in the neuro-
virulence of reoviruses and polyomaviruses (8, 9). Modulating
SA binding affinity has also been shown to influence the patho-
genicity of the neurovirulent strain of the minute virus of mice
(MVM) (10).
While no natural isolates from brain tissue have been reported
thus far, adeno-associated viruses (AAV), which are helper-de-
pendent parvoviruses, display a broad spectrum of CNS tropisms
following intracranial or systemic administration in different
hosts (11–17). The cellular tropisms of different AAV strains ob-
served in these studies were mostly neuronal, with a few excep-
tions that can transduce glial cells like astrocytes as well. Similar to
their helper viruses such as Adenoviridae or Herpesviridae (1),
AAV strains undergo interstitial as well as axonal transport within
the CNS (17). However, the molecular bases of this diversity in
AAV transport mechanisms and CNS tropisms are not well un-
derstood. Within this framework, AAV isolates have been shown
to utilize three different glycans—SA, galactose (Gal), and hepa-
ran sulfate (HS)—for cell surface attachment (10). In addition,
several growth factor receptors and integrins have been identified
as being essential for AAV cell entry (18). Our laboratory and
others have recently demonstrated the roles of SA and Gal in de-
termining the systemic fate of different AAV serotypes in mouse
models (19–21).
The African green monkey isolate AAV serotype 4 (AAV4) is
one of the evolutionarily and structurally most distinct serotypes
known to date and displays selective tropism for the ependymal
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lining following intracerebroventricular (ICV) administration in
neonatal and adult mice (22). In addition, AAV4 particles directly
injected into the subventricular zone can transduce astrocytes
forming glial tubes within the rostral migratory stream (RMS).
The functional cell surface attachment factor for AAV4 is
O-linked 2,3-SA (mucin) (21, 23, 24). We previously identified a
novel AAV4 mutant (AAV4.18) that displays decreased affinity
toward 2,3-SA and a transduction-deficient phenotype following
systemic administration in mice (21). In the current study, we
identified a novel glycan that differentially regulates the CNS
transport and cellular tropism of AAV4 and the laboratory-de-
rived mutant strain. Unlike AAV4, which displays restricted tro-
pism for the ependymal lining, the laboratory-derived AAV4.18
mutant spreads throughout the brain parenchyma and can selec-
tively infect migrating progenitors in the rostral and caudal direc-
tions from a unilateral ICV injection in neonatal mice. Further
biochemical characterization of AAV4 and AAV4.18 in the mouse
brain confirmed a switch in receptor specificity from 2,3-linked
SA to 2,8-linked PSA, a well-established marker of neurogenesis.
MATERIALS AND METHODS
Recombinant AAV vector production. Recombinant AAV4 and mutant
AAV4.18 vectors were generated using an updated triple-plasmid trans-
fection method (25). Briefly, this involved transfection of (i) the pXR4
helper plasmid (26) or the mutant pXR4.18 helper plasmid (21), (b) the
adenoviral helper plasmid pXX6-80, and (c) pTR-CBA-tdTom or pTR-
CBA-Luc plasmids encoding the tdTomato (tdTom) or luciferase (Luc)
reporter genes driven by the chicken beta actin (CBA) promoter and
flanked by inverted terminal repeats (ITRs) derived from the AAV2 ge-
nome. Vector purification was carried out using cesium gradient ultra-
centrifugation, and viral titers were obtained by quantitative PCR using a
Roche Lightcycler 480 (Roche Applied Sciences, Pleasanton, CA) with
primers (IDT Technologies, Ames, IA) designed for the CBA promoter
(forward, 5=-CGT CAA TGG GTG GAG TAT TT-3=; reverse, 5=-GCG
ATG ACT AAT ACG TAG ATG-3=).
In order to generate AAV particles packaging thymidine analog 5-bro-
mo-2=-deoxyuridine (BrdU)-labeled genomes, we adapted a modified
vector production protocol described earlier (27, 28). Briefly, at 1 h after
triple-plasmid transfection, HEK293 producer cells were treated with a
10:1 molar mixture of BrdU and 5-fluoro-2=-deoxyuridine at a final con-
centration of 10 g of BrdU/ml of medium (Invitrogen, Camarillo, CA).
Vectors packaging BrdU-labeled genomes were purified and quantified as
described above.
Cellular transduction assays. CV-1 cells (African green monkey kid-
ney fibroblasts) were seeded at a density of 5  104 cells per well in 24-well
plates and were maintained at 37°C and 5% CO2. The cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and 100 U/ml of penicillin, 100 g/ml of strep-
tomycin, and 2.5 g/ml of amphotericin B (Sigma-Aldrich, St. Louis,
MO). For transduction assays, cells were first exposed to the different
enzymatic treatments as described below.
To cleave long PSA chains, cell cultures were treated with endo-
neuraminidase-N (ABC Scientific, Los Angeles, CA) diluted to 1:5,000 in
DMEM supplemented with 10% FBS for 12 h at 37°C and 5% CO2. To
cleave terminal SA residues, neuraminidase III (neuraminidase) (Sigma-
Aldrich) was diluted to 50 mU/ml in serum-free DMEM and cells were
treated for 3 h at 37°C and 5% CO2. After these treatments, cells were
washed three times with phosphate-buffered saline (1 PBS) and the
medium was replaced with fresh DMEM plus 10% FBS containing AAV4
or AAV4.18 vectors packaging the firefly luciferase transgene, driven by
the CBA promoter at a multiplicity of infection (MOI) of 1,000 viral
genomes (vg) per cell. Cells were lysed at 24 h postransduction, and lucif-
erase transgene expression was quantified using a Victor2 luminometer
(PerkinElmer, Waltham, MA) with D-luciferin as a substrate.
Intracerebroventricular (ICV) injections. All animal experiments
were carried out with BALB/c mice bred and maintained in accordance to
NIH guidelines and as approved by the UNC Institutional Animal Care
and Use Committee (IACUC). Neonatal postnatal day 0 (P0) pups were
rapidly anesthetized by hypothermia by placement on ice for 1 min fol-
lowed by stereotaxic intraventricular cerebral injections. A Hamilton 700
series syringe with a 26-gauge needle (Sigma-Aldrich) was attached to a
KOPF-900 small animal stereotaxic instrument (KOPF instruments, Tu-
junga, CA), and the mice were injected unilaterally in their left lateral
ventricle with a dose of 1  109 vector genome-containing particles (vol-
ume, 3 l) of AAV4 or AAV4.18 vectors packaging the CBA-tdTom re-
porter cassette. Developing mouse brains (P14) were harvested, postfixed,
and immunostained as described in detail below. For tracking BrdU-la-
beled viruses, 7.4  108 vector genome-containing particles in a volume of
5 l were injected into the left lateral ventricles of P0 mice. Neonatal
brains were harvested 2 h postinjection, postfixed in paraformaldehyde,
sectioned, and immunostained as described below. For recombinant siali-
dase coinjection experiments, the vectors were mixed with either 5.2 mU
of neuraminidase type III (sialidase; Sigma-Aldrich) or 1.45 U of endo-
neuraminidase-N (ABC Scientific, Los Angeles, CA) to a total injection
volume of 4.3 l. All neonatal injections were performed 0.5 mm relative
to the sagittal sinus, 2 mm rostral to transverse sinus, and 1.5 mm deep.
Following vector administration, mice were revived under a heat lamp
and rubbed in the bedding before being placed back with the dam.
Tissue processing, confocal microscopy, and immunofluorescence
analysis. Two-week-old mice were sacrificed with an overdose of tribro-
moethanol (Avertin) (0.2 ml of 1.25% solution) followed by transcardial
perfusion of 4% paraformaldehyde in PBS. The brains were removed and
postfixed for 24 h, and 50-m-thick sections were obtained using a Leica
VT 1000S vibrating blade microtome (Leica Biosystems, IL). Free-floating
brain sections were blocked in 10% goat serum and 1% Triton X (Sigma-
Aldrich) in PBS for 1 h prior to overnight incubation with primary mono-
clonal antibodies at 4°C. The following primary antibodies were utilized:
rabbit anti-S100 (Sigma; 1:1,000), mouse anti-GFAP (Abcam-10062,
1:1,000), rabbit anti-Dcx (Abcam-18723, 1:1,000), goat anti-phospho-
histone H3 (anti-PH3) (Millipore; 1:1,000), mouse anti-BrdU (Invitro-
gen; 033900, 1:2,500), rabbit anti-NeuN (Abcam; 104225, 1:750), mouse
anti-PSA-NCAM (DSHB; 1:750), and mouse anti-Rc2/nestin (DSHB;
1:750). Secondary antibodies were raised in goats and conjugated to Alexa
488 or Alexa 647 (Abcam; 1:500). For jacalin staining, we followed the
blocking step with 1.5 h of incubation of free-floating mouse brain sec-
tions in fluorescein isothiocyanate (FITC)-jacalin at room temperature
(Vector Laboratories, Burlingame, CA; 1:40). Jacalin was diluted to a
working concentration of 20 g/ml in 3% goat serum in PBS-Tween
(PBS-T). Immunostained brain sections were visualized using a Zeiss
CLSM 700 confocal laser scanning microscope and analyzed with Zen
Black software. Colocalization (expressed as percent) of tdTomato re-
porter expression with different cell type-specific markers was derived
from the ratio of the number of transduced cells (tdTom) that were
S100/GFAP/Dcx/PH3 and the total number of transduced cells (td-
Tom). Cells were counted in nonoverlapping fields of view of a 200-m2
area in the subependymal zone, rostral migratory stream, olfactory bulb
(OB), or other pertinent regions in the P14 mouse brain.
RESULTS
Substrate-specific neuraminidases have differential effects on
AAV4 transduction in vitro. In most mammalian tissues, SA oc-
cupies the terminal position originating from asparagine-linked
(N-) or serine/threonine-linked (O-) glycoprotein glycans. How-
ever, in the CNS, sialylated glycans are expressed in two forms,
2,3- and 2,6-sialylated glycosphingolipids (gangliosides), as
well as long polymeric chains of 2,8-linked PSA bound to neural
cell adhesion molecule (NCAM) (29) (Fig. 1A). Importantly, the
expression of PSA is known to regulate neural plasticity and play
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an indispensable role in embryonic and adult neurogenesis in the
mammalian brain (30).
It is well known that AAV4 utilizes 2,3-linked SA as the mam-
malian cell surface receptor (23). In order to understand whether
2,8-linked PSA on cell surfaces could also affect AAV4 transduc-
tion, we performed specific neuraminidase treatments to alter the
relative levels of cell surface SA and PSA in vitro. We chose paren-
tal African green monkey kidney CV-1 cells (precursor to Cos
cells) for these experiments due to their highly permissive nature
toward AAV4 transduction (23). As depicted in Fig. 1A, two
classes of neuraminidase enzymes were used: neuraminidase
(Neu), which specifically cleaves 2,3 and 2,6 linkages on SA,
and endoneuraminidase-N (endo-N), which targets 2,8 linkages
on the polymeric PSA chain. We observed that cleavage of SA by
neuraminidase treatment significantly reduced AAV4 transduc-
tion (1 log order of magnitude reduction in luciferase activity;
P  0.005) (Fig. 1B). In contrast, endoneuraminidase-N-medi-
ated cleavage of 2,8-linked PSA significantly enhanced AAV4
transduction (7-fold increase; P  0.05) (Fig. 1C). Taken to-
gether, these preliminary results suggested that levels of SA and
PSA on cell surfaces might differentially regulate AAV4 transduc-
tion. In contrast to AAV4, we observed no significant changes in
the in vitro transduction efficiency of AAV4.18 virions arising
from neuraminidase or endoneuraminidase-N treatments (Fig.
1D and E). However, we interpreted these results with caution due
to the inherently low transduction efficiency of the AAV4.18 mu-
tant in these cells. Earlier studies from our laboratory have dem-
onstrated that the mutant AAV4.18 is likely transduction deficient
in vitro due its low binding affinity for SA on the cell surface (21).
Ependymal transduction efficiency by AAV4.18 is similar to
that of parental AAV4 in neonatal mice. Previous studies have
demonstrated that ICV administration of AAV4 results in robust
gene transfer in the ependymal cells and astrocytes lining the neo-
natal mouse cerebral ventricles (22). We injected P0 mice with
identical titers of AAV4 or AAV4.18 packaging the tdTomato
(tdTom) reporter gene driven by chicken beta actin (CBA) pro-
FIG 1 Effects of substrate-specific neuraminidases on AAV4 and AAV4.18 transduction in vitro. (A) Schematic representation of O-linked 2,3- and 2,6-sialic
acid (top) and 2,8-polysialic acid (bottom) on mammalian cell surfaces. The symbol key defines the different glycan symbols. Black and white arrows represent
the cleavage sites of neuraminidase (Neu) and endoneuraminidase-N (Endo-N) enzymes, respectively. Effects of neuraminidase and endoneuraminidase-N
treatment on AAV4 (B and C) as well as AAV4.18 (D and E) are also shown. CV-1 cells pretreated with each enzyme were incubated with AAV4 or AAV4.18
vectors packaging a CBA-Luc transgene (MOI 	 1,000 vg/cell), and luciferase activity, in relative light units (RLU), was measured at 24 h postinfection. Error bars
represent standard deviations (n 	 3). n.s., not statistically significant; *, P  0.05 as determined by Student t test.
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moter via the ICV route. At 2 weeks postinjection, we carried out
confocal microscopy analysis of sagittal mouse brain sections.
Both vectors displayed efficient tdTom expression (tdTom) in
the subependymal zone (SEZ) (Fig. 2A and B, top row). In order to
further characterize the tdTom cells at a cellular level, we per-
formed immunocolocalization with markers for ependymal cells
(S100) and primary astrocytes (GFAP). As can be seen in Fig. 2D
and E, tdTom cells (red) within the SEZ in both AAV4- and
AAV4.18-injected mouse brains show significant colocalization
with S100 cells (green). Similarly, comparable levels of colocal-
ization of tdTom cells (red) and GFAP cells (green) were also
observed in the SEZs of AAV4- and AAV4.18-treated mice (Fig.
2G and H). These observations were further supported by quan-
titative and statistical analyses that showed no significant differ-
ences in tdTom cells within the SEZ (Fig. 2C) or the percentage
of colocalization with cellular markers (S100 and GFAP) from
AAV4 or AAV4.18 injections (Fig. 2F and I). These results indicate
that both AAV4 and 4.18 vectors can efficiently transduce neona-
tal mouse ependyma. Although not relevant to the current study
focused on the developing brain, it is noteworthy to mention that
similar ependymal transduction profiles for AAV4 and AAV4.18
vectors were observed in adult mouse brains (data not shown).
The AAV4.18 mutant displays expanded tropism for migrating
progenitors. Neuronal progenitors in the SEZ are known to migrate
via the RMS to the OB, where they differentiate into interneurons of
the granular and periglomerular layers in developing and adult ro-
dent brains (31). Confocal microscopy analysis of sagittal sections of
postnatal mouse brains imaged at 2 weeks postinjection revealed
strikingly distinct patterns of transduction between AAV4 and
AAV4.18 vectors. Notably, AAV4.18-injected mice showed signifi-
cantly more tdTom expression in the RMS and OB (
3- and 6-fold
increases, respectively; n 	 4 mice) regions than did AAV4-injected
mice (Fig. 3A and B). We then performed immunostaining for the
migrating neuroblast marker doublecortin (Dcx) and proliferating
cell marker phospho-histone H3 (PH3) to assess the cell types asso-
ciated with the tdTom expression in the RMS and OB. As seen in Fig.
3D and E, tdTom cells (red) within the RMS and the OB in
AAV4.18-injected mouse brains show significantly increased colocal-
ization with Dcx cells (green) compared to that in AAV4-injected
brains. A similar trend showing increased colocalization of tdTom
expression with the PH3 cells was observed in the RMS and, to a
lesser level, in the OB of AAV4.18-injected brains (Fig. 3G and H).
These observations were corroborated by quantitative and statistical
analyses (Fig. 3C, F, and I; *, P  0.05).
FIG 2 Ependymal transduction in the neonatal mouse brain by AAV4 and the AAV4.18 mutant. P0 mice were injected with 1  109 vg of AAV4 (A) or mutant
AAV4.18 (B) packaging a CBA-tdTom transgene into the left lateral ventricle. At 2 weeks postinjection, mice were sacrificed and paraformaldehyde-fixed brains
were sectioned and immunostained. Brain sections were imaged using a Zeiss CLSM 700 confocal laser scanning microscope equipped with 488-nm and 555-nm
excitation filters. Confocal micrographs show tdTom transgene expression in red. Global brain sections (confocal image stitches of representative 50-m
vibratome sagittal sections) and SEZ regions show tdTom expression in the subependymal zone. Immunocolocalization of tdTom gene expression (red) with
ependymal cells (S100; green) (D and E) and primary astrocytes (GFAP, green) (G and H) is indicated by yellow pseudocolor within the S100 and GFAP
merged images. Quantitative assessments of the AAV4-transduced (dark gray bars) or AAV4.18-transduced (light gray bars) cells in the dorsal and ventral SEZ
are indicated by the number of tdTom cells (C) and percent colocalization with S100 cells (F) or GFAP cells (I). Error bars represent standard deviations
(n 	 4). n.s., not statistically significant; *, P  0.05 as determined by Student t test. Representative confocal images are shown.
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Mutant AAV4.18 virions display enhanced CNS spread. In
order to understand the mechanisms underlying the selective tro-
pism of AAV4.18 for progenitors and neuroblasts in the postnatal
CNS, we tracked the distribution of each AAV vector in the mouse
brain parenchyma following ICV injections. To achieve this, we
injected AAV vectors packaging genomes that were labeled with
the thymidine analog bromodeoxyuridine (BrdU) through ICV
injections in neonatal mice. Brains were harvested as early as 2 h
after vector administration and immunostained with an anti-
BrdU antibody to visualize the biodistribution of AAV genomes in
the brain parenchyma. AAV4-injected mice exhibit robust BrdU
staining in the immediate vicinity of the site of injection in the SEZ
and the outer meninges of the neonatal brain, presumably due to
cerebrospinal fluid (CSF) transport (Fig. 4A, middle, arrow). In
contrast, the AAV4.18 vector shows a remarkably diffuse distribu-
tion pattern of BrdU-labeled viral particles not only in the SEZ
(Fig. 4A, right, arrow) but also through the brain parenchyma and
particularly in the cortical regions (Fig. 4A, right, arrowhead).
Immunostaining analysis of brain sections with the endothelial
cell marker CD31 revealed BrdU AAV4.18 genomes (green) ar-
ranged alongside CD31 processes (red) in the cortical regions of
the mouse brain (Fig. 4B, right). In contrast, AAV4 genomes did
not show this phenotype in the cortex (Fig. 4B, middle). It should be
noted that despite the expanded spread of the AAV4.18 genomes,
complete colocalization with endothelial cells was not observed (Fig.
4B, right, inset). This suggests that the selective tropism for migrating
progenitors can, in part, be attributed to the ability of AAV4.18 to
spread across the neonatal brain parenchyma.
Selective enzymatic removal of PSA expands CNS tropism of
AAV4 vectors. The polysialylated form (PSA; 2,8-linked sialic
acid) of neural cell adhesion molecule (NCAM) is expressed in
migrating progenitor cells of the RMS during OB neurogenesis
(32). PSA-NCAM plays a pivotal role in mediating rostral migra-
tion of olfactory bulb precursor cells, whereas deficiencies in ei-
ther PSA or NCAM cause accumulation of progenitor cells in the
SEZ and RMS, resulting in aberrant olfactory histogenesis (32,
33). We coinjected neuraminidase, which selectively cleaves ter-
minal SA residues or endoneuraminidase-N, which cleaves the
polymeric PSA chain with AAV4 packaging the CBA-tdTom re-
porter gene in neonatal P0 mice via the ICV route. Loss of terminal
SA residues due to neuraminidase treatment was confirmed by a
significant reduction in fluorescein isothiocyanate (FITC)-labeled
jacalin staining in the mouse brain (data not shown). Control
injections of AAV4 alone resulted in highly localized tdTom trans-
gene expression in the ependymal lining, which was almost com-
pletely abrogated in neuraminidase-coinjected mice (Fig. 5A and
C, left images). We observed minimal tdTom transgene expres-
sion in migrating progenitors within the RMS and OB by AAV4,
regardless of treatment with neuraminidase (Fig. 5A and C,
middle and right images). Further, no colocalization with PSA-
NCAM immunostaining was observed (Fig. 5B and D). In con-
trast, endoneuraminidase-N treatments increased AAV4-mediated
tdTom transgene expression in the RMS, but more strikingly in
the OB (Fig. 5E, middle and right images) and without affecting
ependymal tdTom transgene expression (Fig. 5E, left image). A
concomitant and significant reduction in PSA-NCAM immuno-
staining in the RMS and OB upon endoneuraminidase-N treat-
ment was also observed (Fig. 5D and F). Taken together, these
results suggest that 2,8-linked PSA negatively regulates AAV4
FIG 3 The AAV4.18 mutant exhibits selective tropism for migrating progenitors. P0 mice were injected with 1  109 vg of AAV4 (A, D, and G) or AAV4.18 (B,
E, and H) packaging the tdTomato reporter transgene driven by a chicken beta actin promoter into the left lateral ventricle. tdTom expression (red) in sagittal
sections of the developing mouse brain, including the subependymal zone (SEZ), rostral migratory stream (RMS), and olfactory bulb (OB) regions, is shown.
Immunocolocalization of AAV4-mediated (A) or AAV4.18-mediated (B) gene expression (tdTom; red) with the migrating neuroblast marker, doublecortin
(Dcx; green) (D and E), and the proliferative cell marker, phospho-histone H3 (PH3; green) (G and H), is shown. White arrows indicate the locations shown at
higher magnification (insets), and immunocolocalized regions are depicted in yellow. Quantitative analyses of the number of tdTom cells (C) and percent
colocalization with Dcx processes (F) and PH3 cells (I) in the RMS and OB regions of AAV4-treated (dark gray bars) or AAV4.18-treated (light gray bars) mice
are shown. Error bars represent standard deviations (n 	 4). n.s., not statistically significant; *, P  0.05 as determined by Student t test. Representative confocal
images are shown.
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spread and potentially competes for 2,3-linked SA binding sites on
the AAV4 capsid.
To further characterize the expanded transduction profile of
AAV4 observed following endoneuraminidase-N coinjections, we
carried out immunocolocalization with several cellular markers.
As discussed above, PSA-NCAM immunostaining was abrogated
due to efficient cleavage of PSA residues from such treatments
(Fig. 6A), and no colocalization with tdTom cells was observed,
as expected. Interestingly, we observed that AAV4-mediated
transgene expression (tdTom) significantly colocalized with
NeuN neurons in the OB (Fig. 6B, arrows, right image). How-
ever, we did not observe colocalization of tdTom cells with the
astrocytic marker, GFAP, or the radial glial marker, RC2/nestin
(Fig. 6C and D). These results indicate that under conditions dis-
playing reduced PSA levels, AAV4 can efficiently transduce ma-
ture OB neurons. These data are consistent with observations
from cell culture studies described earlier. Thus, it appears that
modulation of PSA levels can influence AAV4 tropism in the
mammalian brain.
The low-affinity AAV4.18 mutant displays expanded tro-
pism for migrating progenitors by exploiting high PSA levels. In
order to dissect the possible mechanism underlying the expanded
tropism displayed by AAV4.18 from ependymal cells toward mi-
grating neuroblasts, we subjected the mutant strain to similar en-
zymatic modulation of SA and PSA levels. Similar to the case with
untreated controls (Fig. 7A and B), coinjection of neuraminidase
III with AAV4.18 did not alter the extent of colocalization between
tdTom and PSA-NCAM cells in the RMS or the OB (Fig. 7C
and D). In contrast, coadministration of endoneuraminidase-N
dramatically altered PSA-NCAM staining throughout the mouse
FIG 4 AAV4.18 particles show enhanced CNS spread. P0 mice were injected with 7.4  108 vg of AAV4 or AAV4.18 packaging BrdU-labeled genomes into the
left lateral ventricle. At 2 h postinjection, mice were sacrificed and paraformaldehyde-fixed brains were sectioned, immunostained, and imaged as outlined in
Materials and Methods. (A) Global anti-BrdU immunostaining (green) in sagittal sections of the brain obtained from mock-treated or AAV4- or AAV4.18-
injected mice into the left lateral ventricle (white arrows). The positions of the cortical regions shown in higher magnification in panel B are indicated by white
arrowheads in panel A. (B) Immunocolocalization of BrdU viral genome-containing particles (green) and anti-CD31, an endothelial cell marker for immu-
nostaining of blood vessels (red), in the cortex. All experiments were carried out in triplicate; representative images are shown.
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FIG 5 SA and PSA play opposing roles in AAV4 transduction within the neonatal mouse brain. P0 mice were coinjected with mixtures of 1  109 vg of AAV4
mixed with PBS (control) (A and B), 3.5 mU of neuraminidase (cleaves 2,3- and 2,6-linked sialic acids) (C and D), or 1.45 U of endoneuraminidase-N (cleaves
2,8-linked polysialic acid) (E and F) into the left lateral ventricle. At 2 weeks postinjection, mice were sacrificed and paraformaldehyde-fixed brains were sectioned
and immunostained. tdTom transgene expression patterns (red) and PSA-NCAM immunostaining (green) resulting from enzymatic desialylations are shown in
the global context or as higher magnifications of the RMS and OB regions. White arrows indicate the locations shown at higher magnification (insets). All
experiments were carried out in triplicate; representative images are shown.
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brain, particularly within the migrating progenitor continuum,
and completely abrogated tdTom reporter gene expression in
AAV4.18-injected mouse brains (Fig. 7E and F). Taken together,
these results support the notion that AAV4.18 has undergone a
complete switch in glycan receptor specificity from terminal 2,3-
linked SA to the polymeric 2,8-linked PSA chain owing to a loss in
SA binding affinity. In turn, AAV4.18 appears to exploit the PSA
glycosylation pattern in the developing brain to efficiently trans-
duce migrating progenitors.
Further characterization of AAV4.18-treated mice coinjected
with neuraminidase revealed a striking correlation between the
pattern of tdTom cells and PSA-NCAM staining along the mi-
grating progenitor RMS-OB continuum (Fig. 8A). No apparent
colocalization was observed with the mature neuronal marker,
NeuN, in the PSA-NCAM-labeled region (Fig. 8B). However, it is
noteworthy that some colocalization was observed between
tdTom and NeuN cells in the periphery of OB (data not
shown). Several tdTom cells along the migratory pathway colo-
calized with the astrocyte marker, GFAP, but not the radial glial
marker, RC2/nestin, in the RMS as well as OB (Fig. 8C and D).
Taken together, these results corroborate the notion that modu-
lating SA and PSA levels in the brain can be differentially exploited
by AAV4 and AAV4.18 to attain strikingly distinct transduction
patterns targeting the ependymal lining, neurons within the OB,
or migrating progenitors in the RMS and OB regions within the
neonatal brain.
DISCUSSION
Successful infection by parvoviruses such as AAV involves a series
of carefully orchestrated events, including cell surface receptor
binding, endocytic uptake, capsid uncoating, nuclear entry, and
genome release followed by second-strand synthesis and subse-
quent transcription. The first step, i.e., parvoviral attachment to
the host cell surface, is mediated by different glycans (10). In the
brain, AAV capsid interactions with heparan sulfate (HS) have
been particularly well studied. Direct parenchymal injection of
AAV serotype 2, which utilizes HS as a primary receptor (34),
results in a prominently neuronal transduction profile (11, 35).
Coinjection of soluble heparin has been shown to improve the
CNS spread and, consequently, transduction efficiency of AAV2
following intracranial injections in rodent models (36, 37). The
ability to bind HS also appears to restrict the CNS transduction
profile of AAV serotype 6 (38). However, this effect can be re-
versed in part by mutating a lysine residue (K531) on the capsid
FIG 6 Removal of PSA expands AAV4 tropism to mature OB neurons. P0 mice were coinjected with 1  109 vg of AAV4 mixed with 1.45 U of endoneuramini-
dase-N into the left lateral ventricle. At 2 weeks postinjection, mice were sacrificed and paraformaldehyde-fixed brains were sectioned and immunostained for
different cellular markers, PSA-NCAM (A), NeuN (B), GFAP (C), and RC2/nestin (D), with specific antibodies as outlined in Materials and Methods. Sagittal
sections of the mouse brain featuring progenitor migration in the rostral migratory stream (RMS) and olfactory bulb (OB) and immunocolocalization of tdTom
transgene expression (red) with each cellular marker (green) are shown. White arrows indicate the locations shown at higher magnification (insets) or
immunocolocalized regions (shown in yellow). All experiments were carried out in triplicate; representative images are shown.
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FIG 7 The AAV4.18 mutant selectively exploits PSA to transduce migrating progenitors. P0 mice were coinjected with mixtures of 1  109 vg of AAV4.18 mixed
with PBS (control) (A and B), 5.2 mU of neuraminidase (cleaves 2,3- and 2,6-linked sialic acids) (C and D), or 1.45 U of endoneuraminidase-N (cleaves 2,8-linked
sialic acid/polysialic acid) (E and F) into the left lateral ventricle. Postfixed sagittal sections of P14 mouse brains displaying tdTom transgene expression patterns
resulting from enzymatic desialylation are shown in the global context or as higher magnifications of the RMS and OB regions. White arrows indicate the
locations shown at higher magnification (insets), and immunocolocalization of tdTom expression (red) with PSA-NCAM staining (green) is depicted in yellow
(B, D, and F). All experiments were carried out in triplicate; representative images are shown.
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surface, which abolishes HS binding (38, 39). These earlier studies
highlight the potential for glycan expression patterns to regulate
viral spread and tropism in the brain.
In the current study, we have characterized a novel AAV mu-
tant that selectively transduces migrating progenitors in the neo-
natal mouse brain. This mutant was originally discovered from a
randomly mutated AAV4 capsid library and characterized as an
SA binding-deficient mutant. When administered systemically,
the AAV4.18 mutant displays attenuated cardiopulmonary tro-
pism in mice due to the low binding affinity toward O-linked
2,3-SA, the cognate receptor for the parental AAV4 serotype (21).
In the neonatal mouse brain, the natural isolate AAV4 exclusively
transduces ependymal cells following ventricular injection (22).
Interestingly, when injected directly into the subependymal zone
(SEZ), AAV4 can transduce type B astrocytes and glia overlying
the RMS (22). Our results now show that this dichotomy poten-
tially arises from the high binding affinity of AAV4 capsids for SA
and PSA, which likely restricts transduction to the ependymal lin-
ing following ICV administration. In contrast, the low-affinity
AAV4.18 mutant can penetrate the ependymal barrier into the
brain parenchyma following a single ICV injection and selectively
transduce migrating neuroblasts and proliferating cells, appar-
ently due to interactions with PSA alone (Fig. 1 to 3). It is note-
worthy that the enhanced spread of AAV4.18 particles to distal
regions of the mouse brain does not result in successful transduc-
tion of mature neurons within these regions. Rather, immunohis-
tochemical analysis suggests that AAV4.18 particles that reach the
cortex are closely associated with the brain microvasculature with-
out actually transducing endothelial cells (Fig. 4). This observa-
tion suggests that interstitial solutes such as viral particles might
exploit paravenous efflux or the “glymphatic” clearance pathway
(40). Correspondingly, we postulate that AAV4.18 particles with
low binding affinity are more likely to be affected by interstitial
fluid transport through white matter tracts and perivascular
spaces, leading to enhanced penetration of brain parenchyma.
We further expanded these findings by evaluating the effect of
selective enzymatic removal of 2,3- or 2,8-linked SA from the mu-
rine brain by ICV injection of substrate-specific neuraminidases.
While AAV4 transduction is completely abrogated by selective SA
removal, AAV4.18 transduction of a subset of cells in the ependy-
FIG 8 AAV4.18 selectively transduces migrating progenitors expressing polysialyated NCAM and GFAP. P0 mice were coinjected with 1  109 vg of AAV4.18
mixed with 5.2 mU of neuraminidase into the left lateral ventricle. Postfixed P14 mouse brains were sectioned and immunostained for different cellular markers,
PSA-NCAM (A), NeuN (B), GFAP (C), and RC2/nestin (D), with specific antibodies as outlined in Materials and Methods. Sagittal sections of the mouse brain
featuring progenitor migration in the rostral migratory stream (RMS) and olfactory bulb (OB) and immunocolocalization of tdTom transgene expression (red)
with each cellular marker (green) are shown. White arrows indicate the locations shown at higher magnification (insets) or immunocolocalized regions (shown
in yellow). All experiments were carried out in triplicate; representative images are shown.
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mal wall, the choroid plexus, and PSA-NCAM migrating pro-
genitors remains unaffected (Fig. 5 to 8). This selective require-
ment of polymeric 2,8-linked PSA chain rather than terminal SA
residues for AAV4.18 transduction was clearly demonstrated by
enzymatic removal. Taken together, these results support the no-
tion that AAV4.18 can not only spread throughout the brain pa-
renchyma but also selectively exploit PSA (2,8-linked SA) to trans-
duce postnatal migrating progenitors in the mouse forebrain.
The expanded receptor usage and selective cellular tropism
displayed by AAV4.18 particles are not a mere coincidence. It is
well known that the linear homopolymer of 2,8-linked sialic acid
(PSA) plays an indispensable role in embryonic and adult neuro-
genesis. Two regions of the brain, namely, the OB and hippocam-
pal dentate gyrus, are persistently neurogenic and undergo con-
stant progenitor chain migration into adulthood in rodents (41).
Despite multiple differences between adult and embryonic neuro-
geneses, consistent PSA-NCAM expression is a feature observed
in both of these regions through adulthood (42). The biochemical
properties of PSA make it a potent negative regulator of cell-cell
adhesion. This is important for successful migration of precursor
cells during neurogenesis (43). This is potentially the reason PSA-
NCAM is highly expressed in the neuronal precursor cells during
olfactory neurogenesis (43). Furthermore, the enzymatic removal
of PSA using endoneuraminidase-N treatment disrupts the RMS,
leading to neuroblast dispersion to unspecific regions like the cor-
tex and striatum (32). Thus, the selective transduction of migrat-
ing progenitors by AAV4.18 can be directly attributed to the ex-
pression patterns of this unique glycan attachment factor that can
vary with the developmental stage of the host organism.
Certain gaps still remain in our understanding of the proposed
AAV-PSA interactions. First, PSA does not appear to functionally
influence the tropism or transduction efficiency of AAV4 or re-
lated mutants in physiological settings other than the CNS, such as
the heart and lung following intravenous administration (21). It is
likely that the developing brain provides a unique setting for this
novel virus-glycan interaction. Second, the structural coordinates
that mediate PSA recognition by AAV4 and the mutant virion
remain to be determined. Preliminary structural modeling re-
vealed altered surface electrostatics for the AAV4.18 mutant in
comparison with the parental AAV4 strain (data not shown). It is
tempting to speculate that manipulation of capsid surface charge
density might decrease affinity for branched or linear 2,3-linked
SA glycans while simultaneously imparting the expanded poten-
tial to recognize the negatively charged PSA glycopolymer. These
hypotheses warrant further structural and biophysical analysis
outside the scope of the current study. Nevertheless, our overall
approach helps understand the functional implications of altering
virus-glycan interactions in the CNS and the impact of develop-
mentally regulated or disease-specific glycan expression profiles
on virus neurotropism. Simultaneously, we provide a roadmap
for engineering viruses to favor certain glycan architectures for
gene transfer applications in the brain.
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